Cambridge, MA · Founded 2018 · Privately Held (backing)
Developer of a gene writing technology designed to make permanent small and large alterations to the human genome. Tessera Therapeutics is based in Cambridge, MA and was founded in 2018. Its last reported valuation was $650 million in Dec 2024. It has raised $630 million.
Last reported valuation
$650.0M
Oct 2026
Priced at
—
Total raised
$630.0M
Last round
—
Cap table — not yet on record
Tessera Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Tessera Therapeutics with a free account
·The complete investor list: 29 names
·Watch Tessera Therapeutics: the Monday email on marks, rounds and moves
